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Abstract
Objectives. To determine if depressive symptoms assessed near diagnosis associate with future meas-
ures of pain, disability and disease for adolescent patients diagnosed with JIA.
Methods. Data were analysed from JIA patients aged 1116 years recruited to the Childhood Arthritis
Prospective Study, a UK-based inception cohort of childhood-onset arthritis. Depressive symptoms (using
the Mood and Feelings Questionnaire; MFQ), active and limited joint count, disability score (Childhood
Health Assessment Questionnaire), pain visual analogue scale and patient’s general evaluation visual
analogue scale were collected. Associations between baseline measures (first visit to paediatric rheuma-
tologist) were analysed using multiple linear regression. Linear mixed-effect models for change in the
clinical measures of disease over 48 months were estimated including MFQ as an explanatory variable.
Results. Data from 102 patients were analysed. At baseline, median (IQR) age was 13.2 years
(11.914.2 years) and 14.7% scored over the MFQ cut-off for major depressive disorder. At baseline,
depressive symptoms significantly associated with all clinical measures of disease (P4 0.01). High base-
line depressive symptoms scores predicted worse pain (P4 0.005) and disability (P4 0.001) 12 months
later but not active and limited joint counts.
Conclusions. Adolescent patients with JIA and depressive symptoms had more active joints, pain and
disability at the time of their first specialist appointment. The associations between baseline depression and
both pain and disability continued for at least one year, however, this was not the case for active joint count.
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Rheumatology key messages
. Depressive symptoms are highly prevalent in adolescents with JIA in the UK.
. Depressive symptoms predict future disability and pain but not active disease for adolescent JIA patients.
. A psychological intervention study aiming to improve long-term outcomes for adolescent JIA patients is warranted.
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Introduction
Adolescence is recognized by the WHO as ‘the period in
human growth and development that occurs after child-
hood and before adulthood, from ages 10 to 19’ [1].
Adolescence is a time of immense biological, social and
vocational change [2]. It is also a high risk period for the
development of mental health problems with approxi-
mately half of all psychiatric disorders starting between
late adolescence and early adulthood [2]. For these rea-
sons, adolescence is considered an important and yet
vulnerable period of development that is distinct from
both childhood and adulthood.
JIA is defined as arthritis of unknown aetiology that
begins before the age of 16 years and persists for a min-
imum of 6 weeks [3]. It comprises seven distinct cate-
gories of heterogeneous conditions as defined by the
ILAR [3]. The prevalence of JIA in the UK is approximately
1 in 1000 children [4].
Adolescents with rheumatic disease experience sub-
stantial functional limitations in leisure, home and school
activities [5]. The causes are most likely multifactorial
revolving around pain, disability, fatigue, disease unpre-
dictability and illness perception [57]. It is therefore un-
surprising that many studies have found that young people
with JIA are at increased risk of experiencing depression
compared with their healthy peers [811]. Furthermore, the
JIA categories that commonly have an age of onset during
adolescence (polyarthritis, extended oligoarthritis and
enthesitis-related arthritis) tend to run a more severe
course and are the least likely of the subtypes to go into
treatment-free remission [12]. This makes it especially per-
tinent to determine the burden of low mood in this age
group with JIA and to explore the relationships between
mood and clinical measures of disease.
For adolescent patients with JIA, the relationship be-
tween mood and clinical measures of disease remains
poorly defined. This is partially due to the difficulty of un-
picking all of the underlying mechanisms as well as the
limitations of the few existing studies that included both
children and adolescents with varying disease duration
and age of onset [13, 14]. To date, no studies have under-
taken a longitudinal analysis of these associations in a
purely adolescent JIA inception cohort.
This study explores the hypothesis that for adolescents
with JIA, depressive symptoms are associated with
clinical measures of disease (active and limited joint
count, disability, pain and the patient’s general evaluation
of disease) at the patient’s first visit to a paediatric
rheumatologist and that baseline depressive symptoms
may predict future clinical outcomes.
Methods
Data for this study came from JIA patients recruited to the
Childhood Arthritis Prospective Study (CAPS), a UK based
inception cohort of childhood onset arthritis. Details of the
study have been described elsewhere [15]. Ethical ap-
proval to undertake the study was given by the UK
Northwest Multicentre Ethics Committee (No. 01/8/104).
Written informed consent from parents/guardians of all
patients was obtained and all able children provided
informed assent. Consent was obtained according to the
Declaration of Helsinki (updated 2008). Patients were
recruited within 6 months of their first visit to a paediatric
rheumatologist. Data collected at the first study visit were
labelled baseline data. Patients were followed up longitu-
dinally at 6 months, annually to 5 years and then at 7 and
10 years.
Clinical and psychological assessments
Depressive symptoms were assessed at baseline using
the long version of the child self-report Mood and
Feelings Questionnaire (MFQ) (Angold A, Costello EJ,
Pickles A, Winder F., unpublished work) with a score of
0 indicating no depressive symptoms and a score of 66
indicating very high depressive symptoms. A score of
527 was used as a cut-off score for major depressive
disorder (MDD). This cut-off score has been shown to
give the best diagnostic confidence with good sensitivity
and specificity [16]. The continuous score version of the
MFQ (066 score) was used in all other analyses.
Clinical measures of disease were recorded; number of
joints considered clinically active or restricted in motion by
the rheumatologist (active and limited joint counts), dis-
ability (Child HAQ), pain (010 cm visual analogue scale;
VAS) and the patient’s general evaluation of disease (PGE:
010 cm VAS).
The anticipated effect size of mood on disease activity
was small. It was therefore important to limit the amount
of variation in disease activity that could be attributed to
other variables. Due to limitations in sample size, not all
variables could be appropriately controlled for in the re-
gression analysis and so a number of inclusion criteria
were applied. Patients selected for inclusion in this ana-
lysis were aged 1116 years at baseline, had completed
the MFQ within 2 months of their baseline assessment,
had an ILAR JIA diagnosis of polyarthritis (RF positive
and negative), oligoarthritis or enthesitis-related arthritis
and had complete data at baseline for all variables
investigated (Fig. 1). There were too few patients in the
systemic arthritis, PsA and undifferentiated arthritis
categories for analysis to be appropriately powered, and
so these patients were excluded from further data ana-
lyses. Patients were excluded if taking oral steroids at
baseline as the effect of oral steroids may have masked
any associations between mood and worsened disease
activity.
Cross sectional analysis of baseline data
Data were tested for normal distribution by the
KolmogorovSmirnov test. Data were not normally distrib-
uted and so non-parametric tests were used. Associations
between clinical measures of disease, age, gender, JIA
category and depressive symptoms at baseline were ana-
lysed using Spearman’s correlation and the MannWhitney
test.
Five separate multiple linear regression models were
performed looking at the association between clinical
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measures of disease and depressive symptoms at base-
line. Each model included a different clinical measure of
disease as the dependent variable. Five separate analyses
were performed due to high collinearity between the differ-
ent clinical measures of disease. Depressive symptoms
(continuous score) were included as the independent vari-
able. Age, gender and use of DMARDs were controlled for
in all models regardless of significance in Spearman’s cor-
relation and the MannWhitney tests. Additionally, for the
disability, pain and PGE models, JIA category was
controlled for. JIA category was not controlled for in the
active and limited joint count models due to high
collinearity. Standardized and unstandardized beta values
are presented.
Longitudinal analysis
Linear mixed effects models for change in clinical meas-
ures of disease and depressive symptoms over 48 months
were estimated. This model implicitly imputes missing
data based on trends in the rest of the study population
data for that variable. As a result, no patients were lost
over time due to missing data. Time was included in the
model as a linear spline with a change point at 12 months,
which allowed for different rates of change between
FIG. 1 Inclusion criteria
Patients were included in the data analysis if they met all criteria shown in the flow chart. Failure to meet any of these
criteria resulted in exclusion. Polyarthritis refers to both RF positive and negative polyarthritis. No missing data refers to the
following variables at baseline: age, gender, JIA category, MFQ score, DMARD use, MFQ score, active and limited joint
counts, disability, pain and the patient’s general evaluation of disease. CHAQ: Child Health Assessment Questionnaire;
MFQ: mood and feelings questionnaire; PGA: patient’s general evaluation; VAS: visual analogue scale.
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012 months and 1248 months. Later time points were not
included due to limited data. Baseline depressive symptoms
were then included in the models of disease outcome as an
explanatory variable. This model was then used to predict
clinical measures of disease over time for a representative
low (2 points) and high (31 points) depressive symptoms
score at baseline. This longitudinal analysis was not pow-
ered to account for other covariates due to the small sample
size. To test the difference between the estimated clinical
measures of disease at 12 months for the representative
high and low baseline depressive symptoms scores, a Z
test for differences in estimated means was calculated.
Data were analysed using SPSS Statistics version 21 (IBM
Corp., Armonk, NY, USA) and STATA/IC version 12
(StataCorp LLC, College Station, TX, USA).
Results
Patient selection
A total of 102 patients were included in the analysis.
Table 1 shows the baseline demographic and clinical
information for the 102 patients included in the analyses.
No patients had been treated with a biologic at baseline.
At baseline, 14.7% of patients scored over the cut-off
score of 27 for MDD (Table 1).
Depressive symptoms associate with clinical
measures of disease at baseline
Relationships between depressive symptoms and measures
of disease outcomes at baseline were first investigated in a
cross-sectional analysis. At baseline in the correlation ana-
lysis, depressive symptoms correlated with active joint count
(r=0.324, P< 0.001), limited joint count (r=0.356, P< 0.001),
disability (r=0.514, P< 0.001), pain (r=0.394, P< 0.001) and
PGE (r= 0.431, P< 0.001). Females had significantly higher
depressive symptoms [median (interquartile range), 15.5
(7.021.0)] than males [10.0 (4.015.5); U= 967.0, P< 0.05].
Depressive symptoms were significantly different between
JIA categories at baseline. Patients with polyarthritis had
significantly higher depressive symptoms [19.0 (14.033.0)]
than patients with oligoarthritis [10.0 (4.016.0); U=427.5,
P< 0.001] and enthesitis-related arthritis [9.5 (8.016.0);
U=156.0, P< 0.05]. There were no significant differences
in depressive symptoms between patients with oligoarthritis
and enthesitis-related arthritis.
The regression analyses showed depressive symptoms
at baseline to be associated with active and limited joint
counts, disability, pain and PGE after accounting for pos-
sible confounding variables (Table 2). The unstandardized
beta coefficient represents how many units the dependent
variable (clinical measures of disease) changes in relation
to a 1-unit increase in the independent variable (depressive
symptoms). As different clinical measures of disease utilize
different units, it is not possible to compare the strength of
the association with MFQ across these measures with
the unstandardized beta values. The standardized beta
coefficient shows how many standard deviations the
dependent variable changes for a 1 S.D. increase in the
independent variable. Therefore, the standardized beta
scores allow comparison of the strength of the differ-
ent associations across different clinical measures of
disease.
Depressive symptoms at baseline predict disability,
pain and PGE at 4 years, but not active and limited
joint counts
Next, we explored whether depressive symptoms at
baseline could predict future clinical measures of disease.
Longitudinal analysis showed the estimated change in
clinical measures of disease and depressive symptoms
over the first 4 years (Fig. 2). Depressive symptoms,
active joint counts, limited joint counts, disability, pain
and PGE all showed a similar profile: improvement
during the first year and then stabilization (Fig. 2).
Depressive symptoms at baseline were then included
in the models of clinical measures of disease over time.
These models were then used to predict clinical measures
of disease over time for a representative low (2 points) and
high (31 points) depressive symptoms score at baseline
(Fig. 3). For all outcomes, levels improved between
baseline and 12 months and then remained stable up to
4 years. At 12 months, the estimated active joint count
TABLE 1 Baseline socio-demographic and clinical data
Variable
All patients, n (%) 102 (100)
Gender, n (%)
Female 58 (56.9)
Male 44 (43.1)
Age (1116 years), median (IQR),
years
13.2 (11.914.2)
Time between first visit to a paedi-
atric rheumatologist and baseline
study visit, median (IQR), months
0.8 (0.31.8)
JIA category, n (%)
Polyarthritis (RF positive and
negative)
31 (30.4)
Oligoarthritis 53 (52.0)
Enthesitis-related arthritis 18 (17.6)
DMARD at baseline, n (%)
Yes 6 (5.9)
No 96 (94.1)
Depressive symptoms, MFQ score
(066), median (IQR)
13.0 (6.020.0)
Patients over cut-off for depressive
symptoms, MFQ score 27+, n (%)
15 (14.7)
Active joint count (072), median
(IQR)
2.0 (1.05.0)
Limited joint count (072), median
(IQR)
1.0 (1.04.0)
Disability, CHAQ (03), median
(IQR)
0.625 (0.0001.125)
Pain, 010 cm VAS, median (IQR) 3.2 (0.96.0)
PGE, 010 cm VAS, median (IQR) 2.5 (0.74.9)
One hundred and two patients meeting the inclusion criteria
were included in subsequent analyses. CHAQ: Child Health
Assessment Questionnaire; MFQ: mood and feelings
questionnaire; PGA: patient’s general evaluation; VAS:
visual analogue scale.
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and limited joint count for those with high and low depres-
sive symptoms at baseline were not significantly different
(Fig. 3). In contrast, the estimated disability and pain
scores at 12 months were significantly worse for those
with high baseline depressive symptoms (Fig. 3). Similar
differences were also found at 48 months. For PGE
at 12 months, there was a significant difference in
estimated PGE scores between those with high and
low baseline depressive symptoms. However, the two
predicted scores had overlapping confidence intervals
(Fig. 3). The estimated clinical measures of disease at
12 months, 95% CIs and Z-score values can also
be found in supplementary Table S1, available at
Rheumatology online.
Discussion
The aim of this study was to investigate the associations
between depressive symptoms and disease activity for
adolescent patients with JIA at their first visit to a paedi-
atric rheumatologist and longitudinally over the following
4 years. At baseline 14.7% of patients had significant
depressive symptoms. A higher number of depressive
symptoms at baseline associated with worsened clinical
measures of disease at baseline. Baseline depression
predicted worse pain and disability for up to 4 years
later, but did not predict active or limited joint counts.
There were a significant number of young people with JIA
who had low mood at baseline; 14.7% of patients scored
TABLE 2 Baseline associations between different disease outcomes and depressive symptoms
Dependent variable
MFQ unstandardized
beta value P-value
95% CI unstandardized
beta
MFQ standardized
beta value
Active joint count 0.196 0.005 0.062, 0.269 0.330
Limited joint count 0.166 0.006 0.050, 0.258 0.283
Disability (CHAQ) 0.022 <0.001 0.012, 0.377 0.032
Pain (010 cm VAS) 0.072 <0.001 0.029, 0.323 0.116
PGE (010 cm VAS) 0.082 <0.001 0.043, 0.390 0.12
At diagnosis, depressive symptoms are significantly associated with active and limited joint count, disability, pain and PGE after
accounting for covariates. Data were analysed using multiple linear regression models. Age, gender and DMARD use were
controlled for. Additionally, for the disability, pain and PGE regression models, JIA category [polyarthritis (RF positive and negative),
oligoarthritis and enthesitis-related arthritis] was additionally controlled for. JIA category was not included in the active and limited
joint count models due to high collinearity. n= 102 adolescent patients with JIA. CHAQ: Child Health Assessment Questionnaire;
MFQ: mood and feelings questionnaire; PGA: patient’s general evaluation; VAS: visual analogue scale.
FIG. 2 Change in clinical measures of disease and depressive symptoms over 48 months
Linear mixed effects models are shown for change in clinical measures of disease and depressive symptoms
over 48 months for adolescent patients with JIA. Disease activity measures explored were active joint count (A),
limited joint count (B), PGE (C), disability (D), pain (E) and depressive symptoms (F). 95% CI is shown. CHAQ: Child
Health Assessment Questionnaire; MFQ: mood and feelings questionnaire; PGA: patient’s general evaluation; VAS: visual
analogue scale.
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over the cut-off score for MDD. There have been few stu-
dies investigating the prevalence of depression in JIA, par-
ticularly during adolescence. Of the few studies that do
exist, prevalence rates reported are between 7 and 23%
[5, 8, 11]. The prevalence of diagnosed depression for
healthy 13- to 15-year-olds in the UK is 1.9% [17].
However, no population norms are available for the MFQ,
making it difficult to directly compare our results with de-
pression rates in adolescents without long-term physical
health conditions. There have been mixed reports as to
whether JIA patients have higher depressive symptoms
than healthy children [13, 18]. However, existing studies
mostly investigated a mixed population of children and
adolescents and use different measures of depressive
symptoms and so cannot be directly compared with our
findings. At baseline, depressive symptoms were higher for
females than for males. This gender difference is well
known. From the age of 13 years, females have an
increased risk of developing depression, and this risk in-
creases throughout adolescence [19].
Methotrexate is known to cause nausea and vomiting in
a high proportion of adolescent patients with JIA [20],
which may impact negatively on mood and quality of
life. However, as only six patients in the present study
were taking DMARDS at baseline, a comparison of de-
pressive symptoms between those taking and not taking
DMARDs at baseline could not be made but does warrant
future investigation for adolescents with JIA. There was no
association between DMARD use at 12 months and
depressive symptoms at 12 months.
Longitudinal analysis showed that all clinical measures
rapidly improved over the first year and then stabilized.
Since patients were recruited to this study within 6 months
of their first visit to a paediatric rheumatologist, in the first
year of this study many patients would have started taking
DMARDs and biologics, begun physiotherapy and may
have adopted new self-management behaviours. All of
these factors may have contributed to the reduced dis-
ease activity scores during the first year of this study. It is
interesting that depressive symptoms also improved over
the first year and then stabilized, rather than continuing to
improve over the following years when disease activity
was generally low. This pattern of depressive symptoms
over time mirrors the pattern of disease activity over time.
There are four possible explanations for this mirrored pat-
tern of symptomology; depressive symptoms may lead to
worsened disease activity, disease activity may lead to de-
pressive symptoms, an external factor common to both
depressive symptoms and disease activity may lead to
this pattern of symptoms over time, or a combination of
all of the above factors. Further studies are required to
test these hypotheses and determine the directionality of
these relationships. The results from our cross sectional
regression analysis and longitudinal analysis showed that
for adolescent JIA patients, baseline depressive symp-
toms were associated with worsened pain and disability
at baseline and this relationship persisted over the next
4 years. For many patients, this may mean worse pain and
disability as they enter adulthood. What few studies there
are into the relationship between mood, pain and disability
FIG. 3 Clinical measures of disease over 48 months for high and low depressive symptoms at baseline
Linear mixed effects models are shown for change in clinical measures of disease over 48 months for adolescent patients
with JIA: active joint count (A), limited joint count (B), disability (CHAQ; C), pain (D) and PGE (E). MFQ at diagnosis
included in all models. Estimated disease activity for high (31 points, solid line) and low (2 points, dashed line) depressive
symptoms shown with 95% CI. Z test for difference between estimated scores; *P < 0.05, **P < 0.01, ***P < 0.001.
CHAQ: Child Health Assessment Questionnaire; MFQ: mood and feelings questionnaire; PGA: patient’s general
evaluation; VAS: visual analogue scale.
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for patients with JIA largely support the findings of this
current study. Depressive symptoms have previously
been shown to associate concurrently with disability and
pain for children and adolescents with JIA [13, 18, 21].
Longitudinally, depressive symptoms have been shown
to predict future pain and disability, but only when initial
levels of pain and disability are low [14]. In order to identify
effective treatment targets it will be important to investi-
gate the inflammatory, cognitive and behavioural mechan-
isms that may explain these relationships in a purely
adolescent JIA population.
For adult RA patients, many studies have shown that
depressive symptoms strongly associate with both
current and future pain and disability [2226]. However,
despite there being more published research in adult
RA patients, the mechanisms behind mood, pain and
disability still remain unclear for these patients.
Depression and pain share common biological pathways.
The decreased noradrenaline and serotonin associated
with depression affect neurotransmission in pain pathways,
resulting in reduced pain inhibition and a worse experi-
ence of pain [27]. Furthermore, adolescents who use
catastrophizing as a coping strategy for pain also report
more depressive symptoms, which may be due to the
rumination type behaviours common to both [28]. This is
particularly relevant for adolescents. The prefrontal cortex
(responsible for self-control) does not fully mature until
adulthood whereas the limbic system (responsible for emo-
tional reactivity) is already fully developed [28]. This results in
a bias towards poor cognitive emotion regulation, which in
turn associates with depressive symptoms [29, 30]. The pain
experienced by JIA patients can lead to reduced physical
activity, particularly if the patient believes that exercising will
cause further joint damage, disability and pain [31, 32]. This
decreased activity may lead to a cycle of physical decondi-
tioning, worsened disability and worsened pain [31, 33]. In
addition, the social withdrawal associated with depression
is likely to contribute to reduced physical activity and ex-
acerbate this cycle [31]. It is important to acknowledge the
effect of worse disability and pain on lifestyle limitations,
quality of life and therefore mood.
We found that baseline depressive symptoms asso-
ciated with higher PGE scores at baseline. However, the
longitudinal results are less clear. At 12 months, the esti-
mated PGE scores were significantly higher with high
baseline depressive symptoms. However, the significance
level was approaching 5% and CIs were overlapping, and
so a firm conclusion is difficult to make. It may be that the
sample is underpowered to detect a difference or that no
true association exists. A previous study looking at chil-
dren and adolescents with JIA found that higher depres-
sive symptoms associated with higher concurrent PGE
scores [18]. No studies that we are aware of have
previously explored this relationship longitudinally.
Our cross-sectional analysis showed that baseline de-
pressive symptoms also associated with a higher active
joint count and limited joint count at baseline. Two studies
have previously explored the association between active
joint count and depressive symptoms for JIA patients in a
cross-sectional analysis but neither study found an asso-
ciation [13, 18], which contradicts our findings. The reason
for this discrepancy is unclear but may be due to differ-
ences in study design and age of patients included. Both
previous studies investigated a mixed population of both
children and adolescents with varying disease duration
(between 5 months and 15 years), had lower sample
sizes, used different measures of depressive symptoms
and did not account for any covariates in their analysis
[13, 18]. Neither study investigated limited joint count.
Our longitudinal analysis showed that after the first year
baseline depressive symptoms no longer associated with
subsequent active joint count or limited joint count. We are
not aware of any previous studies exploring the longitudinal
association between depressive symptoms and these clin-
ical measures of disease in adolescents with JIA. In adult
RA patients, depressive symptoms have been shown to
associate with a higher active joint count at the same
point in time [34] and with a higher tender joint count, phys-
ician VAS and a composite DAS28 2 years later [25]. Other
studies have found no associations [24, 26]. It is important
to bear in mind that these studies were in an adult RA
population and so cannot be directly compared with the
results from our analysis in adolescent JIA patients.
The association between active inflammatory disease and
depressive symptoms may partially be explained by the in-
flammatory theory of depression, which states that depres-
sion can be driven by peripheral inflammation [35]. This
means that patients with chronic inflammatory diseases,
such as JIA, may have an increased susceptibility to de-
veloping depression. This theory is supported by proof of
concept studies in adults [3638], children [39] and mouse
models [40]. Depressive symptoms have been shown to as-
sociate with changes in glucocorticoid sensitivity [25, 41],
increased oxidative stress [42, 43], changes in lymphocyte
populations [44, 45] and inflammasome activation [46]. One
may hypothesize that these changes may contribute in
some adolescent patients with JIA towards lowering the
threshold for flares. However, it is important to acknowledge
that the directionality behind the association between in-
flammation and depression remains unclear and is likely to
be multifactorial and bi-directional.
This study has some limitations. Though the MFQ is a
widely used and accepted measure of depression with
excellent reliability and validity [16, 47], it was originally
designed to screen for severe depressive symptoms in
psychiatric patients and so is not so sensitive to lower
levels of depressive symptoms. While it has been useful
to identify patients over the cut-off score for MDD in this
population, the MFQ may not be sensitive enough in
detecting or measuring low-level depressive symptoms.
The longitudinal analysis was not powered to include
age, gender, medication use and JIA category as con-
founders due to study dropouts over time.
This study has shown for the first time that depressive
symptoms are highly prevalent in adolescents with JIA
in the UK. This finding justifies actively screening for
depressive symptoms in routine clinical practice. We
have also shown that depressive symptoms associate
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with worse pain, disability and active disease. Crucially,
depressive symptoms at baseline predict future disability
and pain but not active disease. This work highlights the
need for a psychological intervention study with the aim
of improving long-term outcomes for adolescents with
JIA.
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